BiotechTube
GreenJay Therapeutics

GreenJay Therapeutics

Cambridge, United States· Est.
greenjaytherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $5M

Overview

GreenJay Therapeutics is a private, pre-revenue biotech founded in 2022, developing a safer IV formulation of busulfan called Bulanta™. The technology aims to replace current solvent-laden formulations, potentially reducing patient toxicity while maintaining efficacy in chronic myeloid leukemia (CML) and other stem cell transplant settings. The company has completed key manufacturing milestones and a Series A financing round, positioning it for late-stage regulatory filings.

OncologyHematology

Technology Platform

Proprietary drug reformulation technology focused on eliminating harmful Class 2 solvents (e.g., DMA) from intravenous chemotherapeutics to improve safety profiles.

Funding History

1
Total raised:$5M
Seed$5M

Opportunities

Bulanta™ addresses a clear toxicity issue in a standard-of-care drug, positioning it for rapid adoption in the stem cell transplant setting.
Significant off-label use in AML and other cancers provides a straightforward path for label expansion and major market growth.
The solvent-elimination technology could potentially be applied to reformulate other injectable drugs with similar excipient problems.

Risk Factors

The company faces regulatory risk if the FDA requires additional clinical data beyond bioequivalence.
As a small, virtual firm with limited capital following a recent CEO loss, it is heavily dependent on securing a commercialization partner and raising additional funds.
It must compete against entrenched, low-cost generic versions of busulfan.

Competitive Landscape

GreenJay's primary competition is the existing generic IV busulfan market. Its key advantage is a superior safety profile due to the absence of a toxic solvent. There is no known direct competitor developing a solvent-free IV busulfan. Indirect competition includes other conditioning regimens (e.g., based on total body irradiation or other chemotherapies), but busulfan is a well-established cornerstone agent.

More companies in Drug Delivery & Formulation →More companies in United States →